The present study confirmed that levels of tCho are higher in more aggressive breast cancer phenotypes, including tumors with HER-2/neu overexpression and TNBC [9–11], with similar findings observed in HR+/HER2- luminal-type breast cancer. This evidence concerns the gene ERBB2 and breast cancer.